In June 2025, the EMAs safety division, the Pharmacovigilance Risk Assessment Committee (PRAC), concluded a review of GLP-1 medication and its risk of patients developing NAION
The approved drugs under the target AHR are indicated for various conditions such as psoriasis, dermatitis, inflammatory bowel diseases, neoplasms, and more
Cuando se almacene en el refrigerador, no guarde las plumas de Ozempic directamente junto al elemento de enfriamiento
Similarly, monitoring liver enzymes helps identify gallbladder problems before they become severe
Currently, there are no specific therapies available for SIM, a situation that may be attributed to several factors